The effects of an ActRIIb receptor Fc fusion protein ligand trap in juvenile simian immunodeficiency virus-infected rhesus macaques

FASEB Journal

Volumn 29, Issue 4, 2015, Pages 1165-1175

  O'Connell, Karyn E ^a   Guo, Wen ^b   Serra, Carlo ^b   Beck, Matthew ^a   Wachtman, Lynn ^a,c   Hoggatt, Amber ^a   Xia, Dongling ^a   Pearson, Chris ^a   Knight, Heather ^a,d   O'Connell, Micheal ^a   Miller, Andrew D ^a,e   Westmoreland, Susan V ^a,d   Bhasin, Shalender ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^d ABBVIE INC   (United States)

^e Cornell University College of Veterinary Medicine ^*  (United States)

Author keywords

AIDS; Cachexia; HIV; Muscle wasting; Nonhuman primate

Indexed keywords

ACTIVIN RECEPTOR; ACTIVIN RECEPTOR TYPE 2B; ACTIVIN RECEPTOR TYPE 2B FC PROTEIN; FC RECEPTOR; HYBRID PROTEIN; LIGAND; MYOSTATIN; PLACEBO; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; ACTIVIN RECEPTOR 2; ACTIVIN RECEPTOR TYPE II-B; IMMUNOGLOBULIN FC FRAGMENT; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARM CIRCUMFERENCE; ARTICLE; ATYPICAL MYCOBACTERIOSIS; AUTOPSY; BODY COMPOSITION; BODY MASS; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CHEST CIRCUMFERENCE; COMPARATIVE STUDY; CONTROLLED STUDY; DIARRHEA; DRUG EFFECT; DUAL ENERGY X RAY ABSORPTIOMETRY; ENTEROPATHOGENIC ESCHERICHIA COLI; EPISTAXIS; FAT MASS; GIANT CELL; GINGIVA HYPERPLASIA; HEMATOCRIT; IMMUNOHISTOCHEMISTRY; JUVENILE ANIMAL; LEAN BODY WEIGHT; LEUKOCYTE COUNT; MALE; MORPHOMETRICS; MUSCLE ATROPHY; MUSCLE HYPERTROPHY; NONHUMAN; OPPORTUNISTIC INFECTION; ORGAN WEIGHT; PNEUMONIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHESUS MONKEY; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; TRICEPS BRACHII MUSCLE; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; GENETICS; HIV WASTING SYNDROME; HUMAN; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; SIMIAN IMMUNODEFICIENCY VIRUS; SKELETAL MUSCLE; UPREGULATION; WEIGHT GAIN;

HUMAN IMMUNODEFICIENCY VIRUS; MACACA MULATTA; PRIMATES; SIMIAN IMMUNODEFICIENCY VIRUS;

ACTIVIN RECEPTORS, TYPE II; ANIMALS; DISEASE MODELS, ANIMAL; HEMATOCRIT; HIV WASTING SYNDROME; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; LIGANDS; MACACA MULATTA; MALE; MUSCLE, SKELETAL; MYOSTATIN; RECOMBINANT FUSION PROTEINS; RNA, MESSENGER; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; TRANSFORMING GROWTH FACTOR BETA; UP-REGULATION; WEIGHT GAIN;

EID: 84937389611     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.14-257543     Document Type: Article

References (61)

1. Fearon, K. C., Glass, D. J., and Guttridge, D. C. (2012) Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab. 16, 153-166
2. Martins, T., Vitorino, R., Moreira-Gonçalves, D., Amado, F., Duarte, J. A., and Ferreira, R. (2014) Recent insights on the molecular mechanisms and therapeutic approaches for cardiac cachexia. Clin. Biochem. 47, 8-15
3. Wüst, R. C. I., Degens, H. (2007) Factors contributing to muscle wasting and dysfunction in COPD patients. Int. J. COPD 2, 289-300
4. Rajan, V. R., and Mitch, W. E. (2008) Muscle wasting in chronic kidney disease: the role of the ubiquitin proteasome system and its clinical impact. Pediatr. Nephrol. 23, 527-535
5. Kusko, R. L., Banerjee, C., Long, K. K., Darcy, A., Otis, J., Sebastiani, P., Melov, S., Tarnopolsky, M., Bhasin, S., and Montano, M. (2012) Premature expression of a muscle fibrosis axis in chronic HIV infection. Skeletal Muscle 2, 1-12
6. Scherzer, R., Heymsfield, S. B., Lee, D., Powderly, W. G., Tien, P. C., Bacchetti, P., Shlipak, M. G., and Grunfeld, C.; Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM). (2011) Decreased limb muscle and increased central adiposity are associated with 5-year all-cause mortality in HIV infection. AIDS 25, 1405-1414
7. Erlandson, K. M., Allshouse, A. A., Jankowski, C. M., MaWhinney, S., Kohrt, W. M., and Campbell, T. B. (2013) Functional impairment is associated with low bone and muscle mass among persons aging with HIV infection. J. Acquir. Immune Defic. Syndr. 63, 209-215
8. Shikuma, C. M., Valcour, V. G., Ratto-Kim, S., Williams, A. E., Souza, S., Gerschenson, M., Day, L., Kim, J. H., and Shiramizu, B. (2005) HIV-associated wasting in the era of highly active antiretroviral therapy: a syndrome of residual HIV infection in monocytes and macrophages? Clin. Infect. Dis. 40, 1846-1848
9. Wanke, C. A., Silva, M., Knox, T. A., Forrester, J., Speigelman, D., and Gorbach, S. L. (2000) Weight loss and wasting remain common complications in individuals infected with human immunodeficiency virus in the era of highly active antiretroviral therapy. Clin. Infect. Dis. 31, 803-805
10. Cuerda, C., Zugasti, A., Bretón, I., Camblor, M., Miralles, P., and García, P. (2005) Treatment with nandrolone decanoate and megestrol acetate in HIV-infected men. Nutr. Clin. Pract. 20, 93-97
11. Moyle, G. J., Daar, E. S., Gertner, J. M., Kotler, D. P., Melchior, J.-C., O'brien, F., and Svanberg, E.; Serono 9037 Study Team. (2004) Growth hormone improves lean body mass, physical performance, and quality of life in subjects with HIV-associated weight loss or wasting on highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 35, 367-375
12. Gullett, N. P., Hebbar, G., and Ziegler, T. R. (2010) Update on clinical trials of growth factors and anabolic steroids in cachexia and wasting. Am. J. Clin. Nutr. 91, 1143S-1147S
13. Mulligan, K., Zackin, R., Von Roenn, J. H., Chesney, M. A., Egorin, M. J., Sattler, F. R., Benson, C. A., Liu, T., Umbleja, T., Shriver, S., Auchus, R. J., and Schambelan, M.; ACTG 313 Study Team. (2007) Testosterone supplementation of megestrol therapy does not enhance lean tissue accrual in men with human immunodeficiency virus-associated weight loss: a randomized, double-blind, placebo-controlled, multicenter trial. J. Clin. Endocrinol. Metab. 92, 563-570
14. Loprinzi, C. L., Schaid, D. J., Dose, A. M., Burnham, N. L., and Jensen, M. D. (1993) Body-composition changes in patients who gain weight while receiving megestrol acetate. J. Clin. Oncol. 11, 152-154
15. Simon, D., Alberti, C., Alison, M., Le Henaff, L., Chevenne, D., Boizeau, P., Canal, A., Ollivier, G., Decostre, V., Jacqz-Aigrain, E., Carel, J. C., Czernichow, P., and Hogrel, J. Y. (2013) Effects of recombinant human growth hormone for 1 year on body composition and muscle strength in children on long-term steroid therapy: randomized controlled, delayed-start study. J. Clin. Endocrinol. Metab. 98, 2746-2754
16. Lee, S. J., and McPherron, A. C. (2001) Regulation of myostatin activity and muscle growth. Proc.Natl.Acad.Sci.USA98, 9306-9311
17. McPherron, A. C., Lawler, A. M., and Lee, S.-J. (1997) Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 387, 83-90
18. Gonzalez-Cadavid, N. F., Taylor, W. E., Yarasheski, K., Sinha-Hikim, I., Ma, K., Ezzat, S., Shen, R., Lalani, R., Asa, S., Mamita, M., Nair, G., Arver, S., and Bhasin, S. (1998) Organization of the human myostatin gene and expression in healthy men and HIV-infected menwithmusclewasting. Proc.Natl.Acad.Sci.USA95, 14938-14943
19. Elkina, Y., von Haehling, S., Anker, S. D., and Springer, J. (2011) The role of myostatin in muscle wasting: an overview. Journal of Cachexia, Sarcopenia and Muscle 2, 143-151
20. Mosher, D. S., Quignon, P., Bustamante, C. D., Sutter, N. B., Mellersh, C. S., Parker, H. G., and Ostrander, E. A. (2007) A mutation in the myostatin gene increases muscle mass and enhances racing performance in heterozygote dogs. PLoS Genet. 3, e79
21. Chisada, S., Okamoto, H., Taniguchi, Y., Kimori, Y., Toyoda, A., Sakaki, Y., Takeda, S., and Yoshiura, Y. (2011) Myostatin-deficient medaka exhibit a double-muscling phenotype with hyperplasia and hypertrophy, which occur sequentially during post-hatch development. Dev. Biol. 359, 82-94
22. Kambadur, R., Sharma, M., Smith, T. P. L., and Bass, J. J. (1997) Mutations in myostatin (GDF8) in double-muscled Belgian Blue and Piedmontese cattle. Genome Res. 7, 910-916
23. Schuelke, M., Wagner, K. R., Stolz, L. E., Hübner, C., Riebel, T., Kömen, W., Braun, T., Tobin, J. F., and Lee, S.-J. (2004) Myostatin mutation associated with gross muscle hypertrophy in a child. N. Engl. J. Med. 350, 2682-2688
24. Zimmers, T. A., Davies, M. V., Koniaris, L. G., Haynes, P., Esquela, A. F., Tomkinson, K. N., McPherron, A. C., Wolfman, N. M., and Lee, S. J. (2002) Induction of cachexia in mice by systemically administered myostatin. Science 296, 1486-1488
25. Durieux, A. C., Amirouche, A., Banzet, S., Koulmann, N., Bonnefoy, R., Pasdeloup, M., Mouret, C., Bigard, X., Peinnequin, A., and Freyssenet, D. (2007) Ectopic expression of myostatin induces atrophy of adult skeletal muscle by decreasing muscle gene expression. Endocrinology 148, 3140-3147
26. Elliott, B., Renshaw, D., Getting, S., and Mackenzie, R. (2012) The central role of myostatin in skeletal muscle and whole body homeostasis. Acta Physiol. (Oxf.) 205, 324-340
27. Zhou, X., Wang, J. L., Lu, J., Song, Y., Kwak, K. S., Jiao, Q., Rosenfeld, R., Chen, Q., Boone, T., Simonet, W. S., Lacey, D. L., Goldberg, A. L., and Han, H. Q. (2010) Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell 142, 531-543
28. Liu, W., Thomas, S. G., Asa, S. L., Gonzalez-Cadavid, N., Bhasin, S., and Ezzat, S. (2003) Myostatin is a skeletal muscle target of growth hormone anabolic action. J. Clin. Endocrinol. Metab. 88, 5490-5496
29. Wagner, K. R., Fleckenstein, J. L., Amato, A. A., Barohn, R. J., Bushby, K., Escolar, D. M., Flanigan, K. M., Pestronk, A., Tawil, R., Wolfe, G. I., Eagle, M., Florence, J. M., King, W. M., Pandya, S., Straub, V., Juneau, P., Meyers, K., Csimma, C., Araujo, T., Allen, R., Parsons, S. A., Wozney, J. M., Lavallie, E. R., and Mendell, J. R. (2008) A phase I/II trial of MYO-029 in adult subjects with muscular dystrophy. Ann. Neurol. 63, 561-571
30. Freeman, L. M., Mansfield, K. G., Lackner, A. A., Naumova, E. N., and Gorbach, S. L. (1999) Survival and failure to thrive in the SIV-infected juvenile rhesus monkey. J. Acquir. Immune Defic. Syndr. 22, 119-123
31. Hendricks, E. E., Ludlage, E., Bussell, S., George, K., Wegner, F. H., and Mansfield, K. G. (2004) Wasting syndrome and disruption of the somatotropic axis in simian immunodeficiency virus-infected macaques with Mycobacterium avium complex infection. J. Infect. Dis. 190, 2187-2194
32. Cline, A. N., Bess, J. W., Piatak, M., Jr., and Lifson, J. D. (2005) Highly sensitive SIV plasma viral load assay: practical considerations, realistic performance expectations, and application to reverse engineering of vaccines for AIDS. J. Med. Primatol. 34, 303-312
33. Westmoreland, S. V., Halpern, E., and Lackner, A. A. (1998) Simian immunodeficiency virus encephalitis in rhesus macaques is associated with rapid disease progression. J. Neurovirol. 4, 260-268
34. Zhao, P., and Hoffman, E. P. (2004) Embryonic myogenesis pathways in muscle regeneration. Developmental Dynamics: An Official Publication of the American Association of Anatomists 229, 380-392
35. Zhang, L., Rajan, V., Lin, E., Hu, Z., Han, H. Q., Zhou, X., Song, Y., Min, H., Wang, X., Du, J., and Mitch, W. E. (2011) Pharmacological inhibition of myostatin suppresses systemic inflammation and muscle atrophy in mice with chronic kidney disease. FASEB J 25, 1653-1663
36. Benny Klimek, M. E., Aydogdu, T., Link, M. J., Pons, M., Koniaris, L. G., and Zimmers, T. A. (2010) Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia. Biochem. Biophys. Res. Commun. 391, 1548-1554
37. Liu, G., and Rondinone, C. M. (2005) JNK: bridging the insulin signaling and inflammatory pathway. Curr. Opin. Investig. Drugs 6, 979-987
38. Vallerie, S. N., and Hotamisligil, G. S. (2010) The role of JNK proteins in metabolism. Sci. Transl. Med. 2, 60rv5
39. Paul, P. K., Gupta, S. K., Bhatnagar, S., Panguluri, S. K., Darnay, B. G., Choi, Y., and Kumar, A. (2010) Targeted ablation of TRAF6 inhibits skeletal muscle wasting in mice. J. Cell Biol. 191,1395-1411
40. Verzola, D., Procopio, V., Sofia, A., Villaggio, B., Tarroni, A., Bonanni, A., Mannucci, I., De Cian, F., Gianetta, E., Saffioti, S., and Garibotto, G. (2011) Apoptosis and myostatin mRNA are upregulated in the skeletal muscle of patients with chronic kidney disease. Kidney Int. 79, 773-782
41. Braga, M., Sinha Hikim, A. P., Datta, S., Ferrini, M. G., Brown, D., Kovacheva, E. L., Gonzalez-Cadavid, N. F., and Sinha-Hikim, I. (2008) Involvement of oxidative stress and caspase 2-mediated intrinsic pathway signaling in age-related increase in muscle cell apoptosis in mice. Apoptosis 13, 822-832
42. Kovacheva, E. L., Hikim, A. P., Shen, R., Sinha, I., and Sinha-Hikim, I. (2010) Testosterone supplementation reverses sarcopenia in aging through regulation of myostatin, c-Jun NH2-terminal kinase, Notch, and Akt signaling pathways. Endocrinology 151, 628-638
43. Meng, Y., Chen, C., Wang, L., Wang, X., Tian, C., Du, J., and Li, H. H. (2013) Toll-like receptor-2 ligand peptidoglycan upregulates expression and ubiquitin ligase activity of CHIP through JNK pathway. Cell. Physiol. Biochem. 32, 1097-1105
44. Hoshikawa, Y., Kanki, K., Ashla, A. A., Arakaki, Y., Azumi, J., Yasui, T., Tezuka, Y., Matsumi, Y., Tsuchiya, H., Kurimasa, A., Hisatome, I., Hirano, T., Fujimoto, J., Kagechika, H., Shomori, K., Ito, H., and Shiota, G. (2011) c-Jun N-terminal kinase activation by oxidative stress suppresses retinoid signaling through proteasomal degradation of retinoic acid receptor a protein in hepatic cells. Cancer Sci. 102, 934-941
45. Girgenrath, S., Song, K., and Whittemore, L. A. (2005) Loss of myostatin expression alters fiber-type distribution and expression of myosin heavy chain isoforms in slow- and fast-type skeletal muscle. Muscle Nerve 31, 34-40
46. McPherron, A. C., and Lee, S. J. (2002) Suppression of body fat accumulation in myostatin-deficient mice. J. Clin. Invest. 109, 595-601
47. Jackson, M. F., Luong, D., Vang, D. D., Garikipati, D. K., Stanton, J. B., Nelson, O. L., and Rodgers, B. D. (2012) The aging myostatin null phenotype: reduced adiposity, cardiac hypertrophy, enhanced cardiac stress response, and sexual dimorphism. J. Endocrinol. 213, 263-275
48. Burgess, K., Xu, T., Brown, R., Han, B., and Welle, S. (2011) Effect of myostatin depletion on weight gain, hyperglycemia, and hepatic steatosis during five months of high-fat feeding in mice. PLoS ONE 6, e17090
49. Guo, W., Wong, S., and Bhasin, S. (2013) AAV-mediated administration of myostatin pro-peptide mutant in adult Ldlr null mice reduces diet-induced hepatosteatosis and arteriosclerosis. PLoS ONE 8, e71017
50. Whittemore, L.-A., Song, K., Li, X., Aghajanian, J., Davies, M., Girgenrath, S., Hill, J. J., Jalenak, M., Kelley, P., Knight, A., Maylor, R., O'Hara, D., Pearson, A., Quazi, A., Ryerson, S., Tan, X.-Y., Tomkinson, K. N., Veldman, G. M., Widom, A., Wright, J. F., Wudyka, S., Zhao, L., and Wolfman, N. M. (2003) Inhibition of myostatin in adult mice increases skeletal muscle mass and strength. Biochem. Biophys. Res. Commun. 300, 965-971
51. Lazanas, M. C., Lambrinoudaki, I. V., Douskas, G. A., Tsekes, G. A., Chini, M. N., and Georgiou, E. K. (2003) Body composition in asymptomatic HIV-infected men: cross-sectional and prospective assessment. Hormones (Athens) 2, 43-48
52. Leyes, P., Martínez, E., and Forga Mde T. (2008) Use of diet, nutritional supplements and exercise in HIV-infected patients receiving combination antiretroviral therapies: a systematic review. Antivir. Ther. (Lond.) 13, 149-159
53. Montano, M., Flanagan, J. N., Jiang, L., Sebastiani, P., Rarick, M., LeBrasseur, N. K., Morris, C. A., Jasuja, R., and Bhasin, S. (2007) Transcriptional profiling of testosterone-regulated genes in the skeletal muscle of human immunodeficiency virus-infected men experiencing weight loss. J. Clin. Endocrinol. Metab. 92, 2793-2802
54. Sattler, F., Bhasin, S., He, J., Chou, C. P., Castaneda-Sceppa, C., Yarasheski, K., Binder, E., Schroeder, E. T., Kawakubo, M., Zhang, A., Roubenoff, R., and Azen, S. (2011) Testosterone threshold levels and lean tissue mass targets needed to enhance skeletal muscle strength and function: the HORMA trial. J. Gerontol. A Biol. Sci. Med. Sci. 66, 122-129
55. Chen, J. L., Walton, K. L., Winbanks, C. E., Murphy, K. T., Thomson, R. E., Makanji, Y., Qian, H., Lynch, G. S., Harrison, C. A., and Gregorevic, P. (2014) Elevated expression of activins promotes muscle wasting and cachexia. FASEB J 28, 1711-1723
56. Lee, S.-J., Lee, Y.-S., Zimmers, T. A., Soleimani, A., Matzuk, M. M., Tsuchida, K., Cohn, R. D., and Barton, E. R. (2010) Regulation of muscle mass by follistatin and activins. Mol. Endocrinol. 24, 1998-2008
57. Lee, S.-J. (2007) Quadrupling muscle mass in mice by targeting TGF-beta signaling pathways. PLoS ONE 2, e789
58. Datta-Mannan, A., Yaden, B., Krishnan, V., Jones, B. E., and Croy, J. E. (2013) An engineered human follistatin variant: insights into the pharmacokinetic and pharmocodynamic relationships of a novel molecule with broad therapeutic potential. J. Pharmacol. Exp. Ther. 344, 616-623
59. Sako, D., Grinberg, A. V., Liu, J., Davies, M. V., Castonguay, R., Maniatis, S., Andreucci, A. J., Pobre, E. G., Tomkinson, K. N., Monnell, T. E., Ucran, J. A., Martinez-Hackert, E., Pearsall, R. S., Underwood, K. W., Seehra, J., and Kumar, R. (2010) Characterization of the ligand binding functionality of the extracellular domain of activin receptor type IIb. J. Biol. Chem. 285, 21037-21048
60. McPherron, A. C., Huynh, T. V., and Lee, S.J. (2009) Redundancy of myostatin and growth/differentiation factor 11 function. BMC Dev. Biol. 9, 24
61. Freeman, L. M., Mansfield, K. G., Goldin, B., Woods, M., Gualtieri, L., Li, W., Bussell, S., Lackner, A., and Gorbach, S. L. (2004) Body-composition changes in the simian immunodeficiency virus-infected juvenile rhesus macaque. J. Infect. Dis. 189, 2010-2015